Overview

A Study of Residual Curarization Incidence in China

Status:
Unknown status
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the incidence of residual curarization in PACU and relevant risk factors.
Phase:
Phase 4
Details
Lead Sponsor:
Peking University First Hospital
Collaborators:
Central South University
China Medical University Hospital
Chinese PLA General Hospital
Eastern Hepatobiliary Surgery Hospital
First Affiliated Hospital of Xinjiang Medical University
First Affiliated Hospital of Zhejiang University
First Affiliated Hospital, Sun Yat-Sen University
Hebei Medical University Fourth Hospital
Peking Union Medical College Hospital
RenJi Hospital
Ruijin Hospital
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai Zhongshan Hospital
The First Affiliated Hospital of Guangzhou Medical University
The First Affiliated Hospital of Zhengzhou University
The First Teaching Hospital of Xinjiang Medical University
Tianjin Medical University General Hospital
Tongji Hospital
West China Hospital
Wuhan Union Hospital, China
Xiangya Hospital of Central South University
Zhujiang Hospital
Treatments:
Atracurium
Bromides
Cisatracurium
Rocuronium
Vecuronium Bromide